Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

ABSTRACT The pharmacokinetics of regorafenib and its active metabolites, M2 and M5, vary widely among individual patients. However, the relationship between these plasma concentrations and therapeutic efficacy remains unclear. Patients with metastatic colorectal cancer (mCRC) receiving regorafenib a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kazuo Kobayashi, Takeru Wakatsuki, Erika Sugiyama, Eiji. Shinozaki, Masataka Tajima, Mariko Ogura, Keisho Chin, Akira Ooki, Hiroki Osumi, Shota Fukuoka, Shohei Udagawa, Keitaro Shimozaki, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Wataru Suzuki, Takashi Yokokawa, Hitoshi Sato, Masakazu Yamaguchi, Kensei Yamaguchi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-11-01
Edice:	Clinical and Translational Science
Témata:	neutrophil to lymphocyte ratio pharmacokinetics polymorphisms progression‐free survival regorafenib
On-line přístup:	https://doi.org/10.1111/cts.70386
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!